Cargando…

Clinical and radiographic spectrum of pathologically confirmed tumefactive multiple sclerosis

Atypical imaging features of multiple sclerosis lesions include size >2 cm, mass effect, oedema and/or ring enhancement. This constellation is often referred to as ‘tumefactive multiple sclerosis’. Previous series emphasize their unifocal and clinically isolated nature, however, evolution of thes...

Descripción completa

Detalles Bibliográficos
Autores principales: Lucchinetti, C. F., Gavrilova, R. H., Metz, I., Parisi, J. E., Scheithauer, B. W., Weigand, S., Thomsen, K., Mandrekar, J., Altintas, A., Erickson, B. J., König, F., Giannini, C., Lassmann, H., Linbo, L., Pittock, S. J., Brück, W.
Formato: Texto
Lenguaje:English
Publicado: Oxford University Press 2008
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2442427/
https://www.ncbi.nlm.nih.gov/pubmed/18535080
http://dx.doi.org/10.1093/brain/awn098
_version_ 1782156700928704512
author Lucchinetti, C. F.
Gavrilova, R. H.
Metz, I.
Parisi, J. E.
Scheithauer, B. W.
Weigand, S.
Thomsen, K.
Mandrekar, J.
Altintas, A.
Erickson, B. J.
König, F.
Giannini, C.
Lassmann, H.
Linbo, L.
Pittock, S. J.
Brück, W.
author_facet Lucchinetti, C. F.
Gavrilova, R. H.
Metz, I.
Parisi, J. E.
Scheithauer, B. W.
Weigand, S.
Thomsen, K.
Mandrekar, J.
Altintas, A.
Erickson, B. J.
König, F.
Giannini, C.
Lassmann, H.
Linbo, L.
Pittock, S. J.
Brück, W.
author_sort Lucchinetti, C. F.
collection PubMed
description Atypical imaging features of multiple sclerosis lesions include size >2 cm, mass effect, oedema and/or ring enhancement. This constellation is often referred to as ‘tumefactive multiple sclerosis’. Previous series emphasize their unifocal and clinically isolated nature, however, evolution of these lesions is not well defined. Biopsy may be required for diagnosis. We describe clinical and radiographic features in 168 patients with biopsy confirmed CNS inflammatory demyelinating disease (IDD). Lesions were analysed on pre- and post-biopsy magnetic resonance imaging (MRI) for location, size, mass effect/oedema, enhancement, multifocality and fulfilment of Barkhof criteria. Clinical data were correlated to MRI. Female to male ratio was 1.2 : 1, median age at onset, 37 years, duration between symptom onset and biopsy, 7.1 weeks and total disease duration, 3.9 years. Clinical course prior to biopsy was a first neurological event in 61%, relapsing–remitting in 29% and progressive in 4%. Presentations were typically polysymptomatic, with motor, cognitive and sensory symptoms predominating. Aphasia, agnosia, seizures and visual field defects were observed. At follow-up, 70% developed definite multiple sclerosis, and 14% had an isolated demyelinating syndrome. Median time to second attack was 4.8 years, and median EDSS at follow-up was 3.0. Multiple lesions were present in 70% on pre-biopsy MRI, and in 83% by last MRI, with Barkhof criteria fulfilled in 46% prior to biopsy and 55% by follow-up. Only 17% of cases remained unifocal. Median largest lesion size on T2-weighted images was 4 cm (range 0.5–12), with a discernible size of 2.1 cm (range 0.5–7.5). Biopsied lesions demonstrated mass effect in 45% and oedema in 77%. A strong association was found between lesion size, and presence of mass effect and/or oedema (P < 0.001). Ring enhancement was frequent. Most tumefactive features did not correlate with gender, course or diagnosis. Although lesion size >5 cm was associated with a slightly higher EDSS at last follow-up, long-term prognosis in patients with disease duration >10 years was better (EDSS 1.5) compared with a population-based multiple sclerosis cohort matched for disease duration (EDSS 3.5; P < 0.001). Given the retrospective nature of the study, the precise reason for biopsy could not always be determined. This study underscores the diagnostically challenging nature of CNS IDDs that present with atypical clinical or radiographic features. Most have multifocal disease at onset, and develop RRMS by follow-up. Although increased awareness of this broad spectrum may obviate need for biopsy in many circumstances, an important role for diagnostic brain biopsy may be required in some cases.
format Text
id pubmed-2442427
institution National Center for Biotechnology Information
language English
publishDate 2008
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-24424272009-02-25 Clinical and radiographic spectrum of pathologically confirmed tumefactive multiple sclerosis Lucchinetti, C. F. Gavrilova, R. H. Metz, I. Parisi, J. E. Scheithauer, B. W. Weigand, S. Thomsen, K. Mandrekar, J. Altintas, A. Erickson, B. J. König, F. Giannini, C. Lassmann, H. Linbo, L. Pittock, S. J. Brück, W. Brain Original Articles Atypical imaging features of multiple sclerosis lesions include size >2 cm, mass effect, oedema and/or ring enhancement. This constellation is often referred to as ‘tumefactive multiple sclerosis’. Previous series emphasize their unifocal and clinically isolated nature, however, evolution of these lesions is not well defined. Biopsy may be required for diagnosis. We describe clinical and radiographic features in 168 patients with biopsy confirmed CNS inflammatory demyelinating disease (IDD). Lesions were analysed on pre- and post-biopsy magnetic resonance imaging (MRI) for location, size, mass effect/oedema, enhancement, multifocality and fulfilment of Barkhof criteria. Clinical data were correlated to MRI. Female to male ratio was 1.2 : 1, median age at onset, 37 years, duration between symptom onset and biopsy, 7.1 weeks and total disease duration, 3.9 years. Clinical course prior to biopsy was a first neurological event in 61%, relapsing–remitting in 29% and progressive in 4%. Presentations were typically polysymptomatic, with motor, cognitive and sensory symptoms predominating. Aphasia, agnosia, seizures and visual field defects were observed. At follow-up, 70% developed definite multiple sclerosis, and 14% had an isolated demyelinating syndrome. Median time to second attack was 4.8 years, and median EDSS at follow-up was 3.0. Multiple lesions were present in 70% on pre-biopsy MRI, and in 83% by last MRI, with Barkhof criteria fulfilled in 46% prior to biopsy and 55% by follow-up. Only 17% of cases remained unifocal. Median largest lesion size on T2-weighted images was 4 cm (range 0.5–12), with a discernible size of 2.1 cm (range 0.5–7.5). Biopsied lesions demonstrated mass effect in 45% and oedema in 77%. A strong association was found between lesion size, and presence of mass effect and/or oedema (P < 0.001). Ring enhancement was frequent. Most tumefactive features did not correlate with gender, course or diagnosis. Although lesion size >5 cm was associated with a slightly higher EDSS at last follow-up, long-term prognosis in patients with disease duration >10 years was better (EDSS 1.5) compared with a population-based multiple sclerosis cohort matched for disease duration (EDSS 3.5; P < 0.001). Given the retrospective nature of the study, the precise reason for biopsy could not always be determined. This study underscores the diagnostically challenging nature of CNS IDDs that present with atypical clinical or radiographic features. Most have multifocal disease at onset, and develop RRMS by follow-up. Although increased awareness of this broad spectrum may obviate need for biopsy in many circumstances, an important role for diagnostic brain biopsy may be required in some cases. Oxford University Press 2008-07 2008-06-04 /pmc/articles/PMC2442427/ /pubmed/18535080 http://dx.doi.org/10.1093/brain/awn098 Text en © 2008 The Author(s) http://creativecommons.org/licenses/by-nc/2.0/uk/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/2.0/uk/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Articles
Lucchinetti, C. F.
Gavrilova, R. H.
Metz, I.
Parisi, J. E.
Scheithauer, B. W.
Weigand, S.
Thomsen, K.
Mandrekar, J.
Altintas, A.
Erickson, B. J.
König, F.
Giannini, C.
Lassmann, H.
Linbo, L.
Pittock, S. J.
Brück, W.
Clinical and radiographic spectrum of pathologically confirmed tumefactive multiple sclerosis
title Clinical and radiographic spectrum of pathologically confirmed tumefactive multiple sclerosis
title_full Clinical and radiographic spectrum of pathologically confirmed tumefactive multiple sclerosis
title_fullStr Clinical and radiographic spectrum of pathologically confirmed tumefactive multiple sclerosis
title_full_unstemmed Clinical and radiographic spectrum of pathologically confirmed tumefactive multiple sclerosis
title_short Clinical and radiographic spectrum of pathologically confirmed tumefactive multiple sclerosis
title_sort clinical and radiographic spectrum of pathologically confirmed tumefactive multiple sclerosis
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2442427/
https://www.ncbi.nlm.nih.gov/pubmed/18535080
http://dx.doi.org/10.1093/brain/awn098
work_keys_str_mv AT lucchinetticf clinicalandradiographicspectrumofpathologicallyconfirmedtumefactivemultiplesclerosis
AT gavrilovarh clinicalandradiographicspectrumofpathologicallyconfirmedtumefactivemultiplesclerosis
AT metzi clinicalandradiographicspectrumofpathologicallyconfirmedtumefactivemultiplesclerosis
AT parisije clinicalandradiographicspectrumofpathologicallyconfirmedtumefactivemultiplesclerosis
AT scheithauerbw clinicalandradiographicspectrumofpathologicallyconfirmedtumefactivemultiplesclerosis
AT weigands clinicalandradiographicspectrumofpathologicallyconfirmedtumefactivemultiplesclerosis
AT thomsenk clinicalandradiographicspectrumofpathologicallyconfirmedtumefactivemultiplesclerosis
AT mandrekarj clinicalandradiographicspectrumofpathologicallyconfirmedtumefactivemultiplesclerosis
AT altintasa clinicalandradiographicspectrumofpathologicallyconfirmedtumefactivemultiplesclerosis
AT ericksonbj clinicalandradiographicspectrumofpathologicallyconfirmedtumefactivemultiplesclerosis
AT konigf clinicalandradiographicspectrumofpathologicallyconfirmedtumefactivemultiplesclerosis
AT gianninic clinicalandradiographicspectrumofpathologicallyconfirmedtumefactivemultiplesclerosis
AT lassmannh clinicalandradiographicspectrumofpathologicallyconfirmedtumefactivemultiplesclerosis
AT linbol clinicalandradiographicspectrumofpathologicallyconfirmedtumefactivemultiplesclerosis
AT pittocksj clinicalandradiographicspectrumofpathologicallyconfirmedtumefactivemultiplesclerosis
AT bruckw clinicalandradiographicspectrumofpathologicallyconfirmedtumefactivemultiplesclerosis